rethinkTHC Search
Menu
Study breakdown

Olanzapine resolved treatment-resistant cannabinoid hyperemesis syndrome in four patients

Case ReportPreliminary evidence
The takeaway

Four patients with cannabinoid hyperemesis syndrome that did not respond to standard treatments all improved after receiving olanzapine, an atypical antipsychotic.

Emergency medicine physicians, gastroenterologists, and clinicians managing CHS.

4 of 4 treatment-refractory CHS cases remitted with olanzapine

What the researchers found

All four cases of treatment-refractory CHS remitted after olanzapine treatment. Olanzapine blocks multiple neurotransmitter receptors involved in nausea and vomiting. The authors suggest it may be particularly useful when CHS presents alongside psychotic symptoms or agitation.

Why it matters

CHS is increasingly recognized as cannabis use grows, and some cases do not respond to standard anti-emetics or hot showers. Having additional treatment options for refractory cases addresses a real clinical gap.

The numbers in context

4 patients. All had treatment-refractory CHS. All remitted with olanzapine. Olanzapine targets dopamine, serotonin, histamine, and muscarinic receptors involved in emesis.

How the study worked

Case series of 4 patients with treatment-refractory cannabinoid hyperemesis syndrome treated with olanzapine at a single institution. Clinical outcomes documented before and after olanzapine initiation.

What this study cannot tell us

Only 4 cases with no control group. Cannot rule out spontaneous resolution. No standardized dosing protocol reported. Single institution.

How to read the evidence

Very small case series with no controls. Preliminary signal only.

When this study was published

2021 case series.

The bigger picture

Cannabis cessation remains the definitive treatment for CHS, but patients often cannot or will not stop immediately. Olanzapine could serve as a bridge treatment for acute refractory episodes, borrowing from its established role in chemotherapy-induced nausea.

Questions still open

  • What is the optimal olanzapine dose for CHS? Would it work as first-line treatment? Does it address the underlying pathophysiology or just mask symptoms? How does it compare to haloperidol, which has also been tried for CHS?

Common questions

What is cannabinoid hyperemesis syndrome?
CHS is a condition in chronic cannabis users characterized by severe cyclical nausea, vomiting, and abdominal pain. It typically resolves only with cannabis cessation, though hot showers provide temporary relief.
Why might olanzapine work for CHS?
Olanzapine blocks multiple neurotransmitter receptors (dopamine, serotonin, histamine, muscarinic) involved in nausea and vomiting pathways, similar to its mechanism in treating chemotherapy-induced nausea.

Read the original research

Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.

Journal of psychiatric practice, 27(4), 316-321

Citation

Hsu, Jennifer; Herrmann, Zachary; Kashyap, Saurabh; Claassen, Cynthia. (2021). Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.. Journal of psychiatric practice, 27(4), 316-321. https://doi.org/10.1097/PRA.0000000000000564

Explore the wider topic